eloralintide (LY3841136) / Eli Lilly - LARVOL DELTA

Lilly’s experimental obesity drug shows promise in early study (Hastings Tribune) - P1 | N=188 | NCT06916065 | Sponsor: Eli Lilly and Company | "The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months...The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting."

P1 data • Obesity

Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept (ADA 2025) - P2 | "Unlike other amylin agonist molecules (e.g. Cagrilintide), it is designed to have minimal calcitonin activity in the clinic. The 12 wk phase 1, randomized, placebo (PBO) controlled, double blind study evaluated safety, tolerability, PK, and PD of QW SC Elora in participants with obesity or overweight. At 12 wks, Elora QW was well tolerated with minimal GI AEs and resulted in meaningful weight loss. A phase 2 study (NCT06230523) will further explore safety and efficacy of Elora."

P1 data • Metabolic Disorders • Obesity

Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide (ADA 2025) - "Eloralintide demonstrated preclinical improvements in efficacy, GI tolerability, and quality of weight loss compared to the non-selective amylin analog cagrilintide. These findings support clinical investigation of eloralintide as a weight loss therapeutic."

Preclinical • Metabolic Disorders

The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels (ADA 2025) - "Cagrilintide and eloralintide are both AMYR and CTR agonists whereas NN1213 is a selective AMYRs agonist that also decreases body weight in rats."

Preclinical • Metabolic Disorders • Obesity

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=188 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions (Eli Lilly Press Release) - "Eli Lilly and Company...announced that data from studies of...tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago."

Clinical data • Preclinical • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=128 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=188 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=96 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=250 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=1040 | Recruiting | Sponsor: Eli Lilly and Company | N=765 ➔ 1040

Enrollment change • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Recruiting | Trial completion date: Mar 2025 ➔ Oct 2025 | Trial primary completion date: Mar 2025 ➔ Oct 2025

Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=765 | Recruiting | Sponsor: Eli Lilly and Company | N=390 ➔ 765 | Trial completion date: Sep 2025 ➔ Aug 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Eli Lilly and Company | N=70 ➔ 128

Combination therapy • Enrollment change • Monotherapy • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of LY3841136 in Overweight and Obese Participants (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3841136 in Healthy and Overweight Participants (clinicaltrials.gov) - P1 | N=148 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study of LY3841136 in Japanese Participants With Obesity or Overweight (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • Genetic Disorders • Obesity

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (clinicaltrials.gov) - P2 | N=225 | Recruiting | Sponsor: Eli Lilly and Company

New P2 trial • Genetic Disorders • Obesity